Activ Surgical is a technology company.
Activ Surgical is a technology company.
Activ Surgical has raised $73.0M across 4 funding rounds.
Activ Surgical has raised $73.0M in total across 4 funding rounds.
Activ Surgical is a Boston-based digital surgery company founded in 2017, developing a scalable, patent-protected surgical software platform powered by computer vision, AI, machine learning, and augmented reality (AR) to enhance intraoperative decision-making and reduce surgical complications.[1][2][7] Its flagship products include ActivSight, an FDA-cleared imaging module that provides real-time visualization of critical structures like tissue perfusion without dyes, and the ActivInsights AR-based software suite, integrated into existing laparoscopic and robotic systems to serve surgeons worldwide by improving efficiency, accuracy, patient outcomes, and accessibility.[1][4][5][7] The company targets hospitals and surgical teams, addressing preventable errors—such as those from poor visualization—through hardware-agnostic tech that has shown early clinical traction, including the world's first autonomous soft-tissue robotic surgery in 2018 and growing adoption in procedures like bariatric revisions.[2][4][5]
Backed by $45M in Series B funding led by Cota Capital (with Hikma Ventures, DNS Capital, and others), Activ has secured FDA 510(k) clearance in 2021, over 30 patents, and partnerships with Microsoft, NVIDIA, and Qualcomm, fueling commercial rollout and global expansion.[1][5][6][8]
Activ Surgical emerged from a pivotal 2018 milestone: completing the world's first autonomous robotic surgery of soft tissue, highlighting the need for advanced real-time visualization in minimally invasive procedures.[2][3][5] Founded in 2017 and headquartered in Boston, the company was driven by a team with over 100 years of combined medical experience, though specific founders are not detailed in available sources; leadership includes CEO Todd Usen, who has emphasized democratizing surgical care.[1][5] Early traction built on this breakthrough, with FDA clearance for ActivSight in early 2021, first in-human trials, a U.S. patent issuance, and 35% team growth that year, setting the stage for Series B funding in 2022 and integrations with tech giants like Microsoft for Startups.[1][5][6]
Activ Surgical rides the digital surgery wave, blending AI, AR, and edge computing to transform operating rooms amid rising demand for minimally invasive procedures and robotic assistance, where complications from poor visualization affect millions annually.[2][7][8] Timing aligns with post-2021 regulatory wins and funding amid healthcare AI growth, amplified by market forces like aging populations, surgeon shortages, and OR efficiency pressures.[1][5] By enabling "world-class surgery accessible for all" via data-driven insights and global OR connectivity, Activ influences the ecosystem—partnering with giants like NVIDIA to standardize intelligent imaging, reduce errors, and scale autonomous capabilities, potentially reshaping surgical standards from high-resource centers to underserved regions.[3][4][8]
Activ Surgical is poised to expand ActivInsights commercially, leveraging NVIDIA integrations for faster AI deployment and Series B funds for global rollouts, targeting broader adoption in robotics and laparoscopy.[5][8] Trends like edge AI in medtech, AR proliferation, and connected ORs will propel growth, with potential for more FDA nods and data aggregation from worldwide surgeries to refine ML models. Its influence may evolve from visualization pioneer to full surgical intelligence leader, empowering surgeons universally and cutting complications—tying back to its core mission of making every imaging system intelligently lifesaving.[2][7]
Activ Surgical has raised $73.0M in total across 4 funding rounds.
Activ Surgical's investors include Access Biotechnology, Artis Ventures (AV), Atlas Venture, Cota Capital, Digitalis Ventures, Innovation Endeavors, Lightspeed Venture Partners, Pillar VC.
Activ Surgical has raised $73.0M across 4 funding rounds. Most recently, it raised $45.0M Series B in July 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2021 | $45.0M Series B | Access Biotechnology, Artis Ventures (AV), Atlas Venture, Cota Capital, Digitalis Ventures, Innovation Endeavors, Lightspeed Venture Partners, Pillar VC | |
| Jul 1, 2020 | $15.0M Venture Round | Access Biotechnology, Artis Ventures (AV), Atlas Venture, Digitalis Ventures, Innovation Endeavors, Pillar VC | |
| Oct 1, 2019 | $11.0M Series A | Access Biotechnology, Artis Ventures (AV), Atlas Venture, Digitalis Ventures, Innovation Endeavors, Pillar VC | |
| Jul 1, 2017 | $2.0M Seed | Access Biotechnology, Artis Ventures (AV), Atlas Venture, Digitalis Ventures, Innovation Endeavors, Pillar VC |